SOMERVILLE, MA, Oct. 19, 2009 (Marketwire) --

SOMERVILLE, MA -- (Marketwire) -- 10/19/09 -- TIBCO Software Inc. (NASDAQ: TIBX) today announced a strategic push to extend its leadership position in the global life sciences market with the release of several research and clinical analysis solutions, including Integromics Biomarker Discovery 2.0 for TIBCO Spotfire®, TIBCO Spotfire® Lead Discovery 2.0, TIBCO Spotfire® Pipeline Pilot Connector, and TIBCO Spotfire® Clinical Graphics 2.0. These solutions deliver integrated informatics and analysis, are central to research & development efforts in the life sciences industry and can transform the process of bringing life-saving medicines to market. Access to actionable knowledge early in the commercialization process of a new drug can lead to better safety outcomes for patients, and better regulatory and commercial outcomes for the industry.

The TIBCO Spotfire® Enterprise Analytics Platform is designed to become an essential tool for every decision maker in the pharmaceutical/biotech industry -- from the scientist in the lab to the head of R&D. Timely and reliable access to essential scientific and operational data will drive informed decisions leading to better productivity. Data transparency enabled by the ability to integrate with the majority of current data sources further enhances the value of these corporate data assets and improves the quality of key decisions.

"Delivering novel medicines that serve the needs of patients and meet new, more stringent regulatory and reimbursement pressures is becoming increasingly difficult. Pharmaceutical and biotech companies are under increasing pressure to capitalize on all their data assets -- from early Discovery and late stage Clinical Development to financial, logistical and operational data -- to better enable the process of bringing new medicines to market that are safe, efficacious and effective," said Mark Lorion, vice president of Marketing, TIBCO Spotfire.